Literature DB >> 33798954

Immunotherapy in non-small cell lung cancer harbouring driver mutations.

Alfredo Addeo1, Antonio Passaro2, Umberto Malapelle3, Giuseppe Luigi Banna4, Vivek Subbiah5, Alex Friedlaender6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33798954     DOI： 10.1016/j.ctrv.2021.102179

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   13.608


× No keyword cloud information.
  13 in total

1.  Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.

Authors:  Tae Hata; Chikara Sakaguchi; Keita Hirano; Hiroshi Kobe; Masaki Ishida; Takayuki Nakano; Yusuke Tachibana; Nobuyo Tamiya; Shinsuke Shiotsu; Takayuki Takeda; Tadaaki Yamada; Toshihide Yokoyama; Michiko Tsuchiya; Yukio Nagasaka
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

Review 2.  Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Authors:  Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2021-09-06       Impact factor: 6.261

3.  Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer.

Authors:  Emilio Francesco Giunta; Alessio Signori; Howard Jack West; Giulio Metro; Alex Friedlaender; Kaushal Parikh; Giuseppe Luigi Banna; Alfredo Addeo
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

4.  Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.

Authors:  Sanjay Popat; Stephen V Liu; Nicolas Scheuer; Grace G Hsu; Alexandre Lockhart; Sreeram V Ramagopalan; Frank Griesinger; Vivek Subbiah
Journal:  Nat Commun       Date:  2022-06-17       Impact factor: 17.694

Review 5.  Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.

Authors:  Danielle Brazel; Gianna Kroening; Misako Nagasaka
Journal:  BioDrugs       Date:  2022-10-18       Impact factor: 7.744

6.  Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.

Authors:  Antonio Passaro; Ilaria Attili; Alessandra Rappa; Davide Vacirca; Alberto Ranghiero; Caterina Fumagalli; Juliana Guarize; Lorenzo Spaggiari; Filippo de Marinis; Massimo Barberis; Elena Guerini-Rocco
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

Review 7.  EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.

Authors:  Alex Friedlaender; Vivek Subbiah; Alessandro Russo; Giuseppe Luigi Banna; Umberto Malapelle; Christian Rolfo; Alfredo Addeo
Journal:  Nat Rev Clin Oncol       Date:  2021-09-24       Impact factor: 66.675

Review 8.  Precision therapy for RET-altered cancers with RET inhibitors.

Authors:  Kyaw Z Thein; Vamsidhar Velcheti; Blaine H M Mooers; Jie Wu; Vivek Subbiah
Journal:  Trends Cancer       Date:  2021-08-12

Review 9.  Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.

Authors:  Sagun Parakh; Matthias Ernst; Ashleigh R Poh
Journal:  Cancers (Basel)       Date:  2021-12-11       Impact factor: 6.639

10.  Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report.

Authors:  Ling Gu; Xiaoying Wei; Zixiang Zhang; Wei Heng
Journal:  Clin Med Insights Oncol       Date:  2022-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.